News
アキュリスファーマのニュースリリースは、当社の企業活動を報道関係者の皆さまへ情報提供することを目的に発信しております。医薬品・開発品の情報を含む場合がありますが、広告・プロモーションや医学的なアドバイス等を目的とするものではありません。
ACULYS News Releases are issued to provide press journalists with the information related to our company. In some instances, information on products or drug candidates under development may be included, but it is not intended for promotional or advertising purposes, or as medical advice, etc.
- Aculys Pharma receives orphan drug designation for a diazepam nasal spray: an antiepileptic drug for epileptic seizures
- Aculys Pharma Announces Leadership Change
- Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
- Aculys Pharma and Medical Note enter into a partnership to raise awareness on sleep disorders
- Aculys Pharma joins the Sleep Services Consortium of Japan
- Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome
- Aculys Pharma and Four H Initiate Research Collaboration using Wearable Devices to Study Sleep Disorders in Japan
- Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
- Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan
- Aculys Pharma has entered into a comprehensive collaboration agreement with KNOCK ON THE DOOR to solve social issues related to recurrent epileptic seizures
